Volume 4.40 | Oct 15

Pancreatic Cell News 4.40 October 15, 2013
Pancreatic Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pancreatic Cell News on Twitter
 
TOP STORY
DCLK1 Marks a Morphologically Distinct Subpopulation of Cells with Stem Cell Properties in Pre-Invasive Pancreatic Cancer
Using mouse models and human pancreatic cancer cell lines, scientists investigated whether pre-invasive pancreatic neoplasia contains a subpopulation of cells with distinct morphologies and cancer stem cell-like properties. [Gastroenterology] Abstract
Take the 'if' out of 'diff': Reduce variability when differentiating to endothelial cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
DIABETES & PANCREATITIS

MicroRNA-26a Targets Ten Eleven Translocation Enzymes and Is Regulated during Pancreatic Cell Differentiation
The molecular mechanisms that regulate Ten eleven translocations (TETs)/thymine DNA glycosylase (TDG) expression and their role in cellular differentiation, including that of the pancreas, are not known. Scientists report that TET1/2/3 and TDG can be direct targets of microRNA-26a. [Proc Natl Acad Sci USA] Abstract

Artificial Three-Dimensional Niches Deconstruct Pancreas Development In Vitro
Researchers established three-dimensional culture conditions in Matrigel that enable the efficient expansion of dissociated mouse embryonic pancreatic progenitors. By manipulating the medium composition they generated either hollow spheres, which are mainly composed of pancreatic progenitors, or complex organoids that spontaneously undergo pancreatic morphogenesis and differentiation. [Development]
Full Article

Cocoa Flavonoid Epicatechin Protects Pancreatic Beta Cell Viability and Function against Oxidative Stress
Researchers investigated the chemo-protective effect of epicatechin against oxidative stress induced by tert-butylhydroperoxide on Ins-1E pancreatic beta cells. [Mol Nutr Food Res] Abstract

Insulin Secretion and Ca2+ Dynamics in β-Cells Are Regulated by PERK eIF2α Kinase in Concert with Calcineurin
Scientists used a newly developed and highly specific inhibitor of EIF2AK3 (PERK) to determine the immediate effects of acute ablation of PERK activity. They found that inhibition of PERK in human and rodent β-cells causes a rapid inhibition of secretagogue-stimulated subcellular Ca2+ signaling and insulin secretion. [J Biol Chem] Abstract | Full Article

Knockdown of Prolactin Receptors in a Pancreatic Beta Cell Line: Effects on DNA Synthesis, Apoptosis, and Gene Expression
Researchers treated rat insulinoma cells with a PRL receptor (PRLR) siRNA to determine if PRLR signaling is required for beta cell DNA synthesis and cell survival and to identify beta cell cycle genes whose expression depends upon lactogen action. [Endocrine] Abstract

PANCREATIC CANCER

MicroRNAs Co-operatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression
Scientists identified three microRNAs (miRNAs) that acted as cooperative repressors of a network of tumor suppressor genes that included PDCD4, BTG2, and NEDD4L. Inhibition of MIR21, MIR23A, and MIR27A had synergistic effects in reducing proliferation of pancreatic ductal adenocarcinoma cells in culture and growth of xenograft tumors in mice. [Gastroenterology] Abstract

Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer
Researchers used a genome-wide pharmacologic transcriptome approach to identify novel cancer-specific DNA methylation alterations in pancreatic cancer cell lines. [Clin Cancer Res] Abstract

Selective Disruption of Rb-Raf-1 Kinase Interaction Inhibits Pancreatic Adenocarcinoma Growth Irrespective of Gemcitabine Sensitivity
To define the anti-tumor effects of RRD-251, cell-cycle analyses, senescence, cell viability, cell migration, anchorage-independent growth, angiogenic tubule formation and invasion assays were performed on gemcitabine sensitive and resistant pancreatic cancer cells. RRD-251 prevented S-phase entry, induced senescence and apoptosis, and inhibited anchorage-independent growth and invasion. [Mol Cancer Ther] Abstract

The Loss of miR-26a-Mediated Post-Transcriptional Regulation of Cyclin E2 in Pancreatic Cancer Cell Proliferation and Decreased Patient Survival
Researchers determined the roles of microRNA (miR)-26a in pancreatic cancer and its association with the survival of patients with pancreatic cancer. miR-26a was expressed in the cytoplasm of pancreatic ductal epithelial cells, whereas its expression was significantly downregulated in pancreatic duct adenocarcinoma tissues compared with that of adjacent benign pancreatic tissues. [PLoS One] Full Article

Enhancement Effect of Dihydroartemisinin on Human γδ T Cell Proliferation and Killing Pancreatic Cancer Cells
Researchers investigated the effect of dihydroartemisinin on human γδ T cell proliferation by MTT assay and killing activity against pancreatic cancer cells SW1990, BxPC-3 and PANC-1 by LDH release assay in vitro. [Int Immunopharmacol] Abstract

Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
 
REVIEWS
Steroid Induced Diabetes: A Clinical and Molecular Approach to Understanding and Treatment
The authors review the pathogenesis, risk factors, diagnosis and treatment principles unique to steroid-induced diabetes. [Diabetes Metab Res Rev] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
 
INDUSTRY NEWS
Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model
Compugen Ltd. announced that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes. [Compugen Ltd.] Press Release

Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program
Ligand Pharmaceuticals Incorporated has opened an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) and has obtained FDA approval to initiate clinical development for its Glucagon Receptor Antagonist program with LGD-6972 for the treatment of type 2 diabetes mellitus. [Ligand Pharmaceuticals Incorporated] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW World Stem Cell Summit 2013
December 4-6, 2013
San Diego, United States

Visit our events page to see a complete list of events in the pancreatic cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Associate – Human and Mouse Stem Cell Biology, Pancreatic and Liver Specification and In Vitro Disease Modeling (Baylor College of Medicine)

Postdoctoral Fellowship – Cellular Metabolism (Lund University)

Postdoctoral Fellow – Molecular Mechanisms of Cancer Progression (University of South Alabama)

Postdoctoral Position – Cardiovascular Development and Diabetes (Cornell University)

Postdoctoral Researcher – Pancreatic Cancer (UT Southwestern Medical Center at Dallas)

Postdoctoral Fellow – Molecular Mechanisms of Cardiovascular Diseases (University of Rochester Medical Center)

Postdoctoral Position – Mechanism of Pancreatic Beta Cell Proliferation (Joslin Diabetes Center/Harvard Medical School)

Faculty Position – Department of Cellular & Structural Biology (The University of Texas Health Science Center at San Antonio)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Pancreatic Cell News: Archives | Events | Contact Us